论文部分内容阅读
目的:探讨新辅助化疗联合手术治疗较传统手术治疗Ib2、IIa2局部晚期宫颈癌的临床疗效。方法:选取2008年6月～2011年12月在黑龙江省哈尔滨医科大学附属第三医院初治宫颈癌患者120例,临床分期为Ib2期、IIa2期,术前均经病理证实为宫颈鳞癌,将其分为两组:研究组(新辅助化疗联合手术治疗组);对照组(单纯手术治疗组)。研究组给予1～2个疗程的新辅助化疗后评估其化疗疗效,有效者化疗结束后行广泛性子宫切除+盆腔淋巴结清扫术;对照组直接行手术治疗。结果:新辅助化疗能够使肿瘤体积较化疗前缩小或消失,临床有效率高达81.43%,从而降低了宫颈癌的临床分期,提高手术的切除率,扩大手术适应征,降低术后病理高危因素,同时手术治疗能保留卵巢功能,提高年轻宫颈癌患者生活质量。结论:术前新辅助化疗可以提高手术治疗局部晚期宫颈癌的临床疗效。
Objective: To investigate the clinical efficacy of neoadjuvant chemotherapy combined with surgical treatment of local advanced cervical cancer Ib2, IIa2 than the traditional surgical treatment. Methods: From June 2008 to December 2011, 120 patients with newly diagnosed cervical cancer were enrolled in the Third Affiliated Hospital of Harbin Medical University, Heilongjiang Province. The clinical stage was stage Ib2 and stage IIa2. Cervical squamous cell carcinoma was confirmed by pathology before operation. Divided into two groups: the study group (neoadjuvant chemotherapy combined surgery group); control group (simple surgery group). The study group was given 1 to 2 courses of neoadjuvant chemotherapy to assess the efficacy of chemotherapy, the effective chemotherapy after the end of a radical hysterectomy + pelvic lymph node dissection; the control group directly underwent surgery. Results: The neoadjuvant chemotherapy can reduce or eliminate the tumor volume compared with before chemotherapy, the clinical effective rate is as high as 81.43%, which reduces the clinical staging of cervical cancer, improves the resection rate, expands the indications for surgery, reduces the postoperative pathological risk factors, At the same time surgical treatment can retain ovarian function and improve the quality of life of young patients with cervical cancer. Conclusion: Preoperative neoadjuvant chemotherapy can improve the surgical treatment of locally advanced cervical cancer clinical efficacy.